Drugmaker AstraZeneca on Wednesday said that its experimental breast cancer treatment improved patient survival without the ...

The results showed statistically significant and clinically meaningful improvement in progression-free survival compared with ...

Pharmaceuticals major AstraZeneca said on Wednesday that its experimental treatment, camizestrant, improved survival in ...

The British drugmaker claimed study success in a first-line setting in breast cancer. Elsewhere, Rezdiffra sales continued to ...

In the Phase III SERENA-6 trial, camizestrant—in combination with CDK-inhibitors—beat out current standard-of-care treatments ...

The pharmaceutical company AstraZeneca has completed the transition to a fully electric vehicle fleet in Switzerland. All of ...

We recently published a list of the 10 Best Vaccine Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where AstraZeneca PLC (NASDAQ: AZN) stands against the other ...

Kiniksa will now focus its development efforts on the IL-1 blocker KPL-387, which it is testing for recurrent pericarditis ...

New York State Common Retirement Fund grew its position in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 7.4% during the 4th ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

Morgan Stanley同样对AstraZeneca表示信心，给予增持评级和GBP145.00的目标价。该机构预计公司收入和每股收益将实现增长。Goldman Sachs虽然将AstraZeneca的目标价下调至GBP150.67，但重申买入评级，理由是公司拥有强大的产品管线，且中国市场的挑战可控。

Beijing appears to be extending an olive branch to the previously under-fire drug maker as it tries to shore up private ...